



This is a repository copy of *An updated systematic review of studies mapping (or cross walking) measures of health related-quality of life to generic preference-based measures to generate utility values.*

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/144129/>

Version: Supplemental Material

---

**Article:**

Mukuria, C., Rowen, D. [orcid.org/0000-0003-3018-5109](https://orcid.org/0000-0003-3018-5109), Harnan, S. et al. (4 more authors) (2019) An updated systematic review of studies mapping (or cross walking) measures of health related-quality of life to generic preference-based measures to generate utility values. *Applied Health Economics and Health Policy*, 17 (3). pp. 295-313. ISSN 1175-5652

<https://doi.org/10.1007/s40258-019-00467-6>

---

This is a post-peer-review, pre-copyedit version of an article published in *Applied Health Economics and Health Policy*. The final authenticated version is available online at:  
<https://doi.org/10.1007/s40258-019-00467-6>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## Appendix 2 Mapping studies

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
15D	AQoL-8D, EQ-5D-5L, HUI3, QWB, SF-6D	Finnish	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [62]
15D	AQoL-8D, EQ-5D-5L, HUI3, QWB, SF-6D	Finnish	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Richardson, 2014 [63]
15D	Depression Anxiety Stress Scales (DASS-21), Kessler Psychological Distress Scale (K10)	Finnish	I	Depression	Australia, USA, UK, Canada, Norway, Germany	Mihalopoulos, 2014 [64]
15D	Diabetes-39	Finnish	I	Diabetes	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [65]
15D	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	Finnish	I	Prostate cancer	Finland	Bergius, 2017 [66]
15D	Fibromyalgia Impact Questionnaire (FIQR)	Finnish	I	Fibromyalgia	Spain	Collado-Mateo, 2017 [67]
15D	MacNew Heart Disease Quality of Life Questionnaire	Finnish	I	Heart disease	Australia, USA, UK, Canada, Norway, Germany	Chen, 2014 [68]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
15D	Sydney Asthma Quality of Life Questionnaire (AQLQ-S)	Finnish	I	Asthma	multi-country	Kaambwa, 2016 [69]
AQoL-4D	National Institutes of Stroke Scale (NIHSS), Barthel Index, SF-36	Australia	I	Stroke	Australia	Mortimer, 2009 [70]
AQoL-4D	SF-36	Australia	I	General population, Outpatients and Inpatients	Australia	Mortimer, 2007 [71]
AQoL-4D	Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)	Australia	I	Arthritis of the knees or hips and Osteoarthritis of the knees or hips	Australia	Ackerman, 2014 [72]
AQoL-8D	15D, EQ-5D-5L, HUI3, QWB, SF-6D	Australia	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [62]
AQoL-8D	15D, EQ-5D-5L, HUI3, QWB, SF-6D	Australia	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Richardson, 2014 [63]
AQoL-8D	Depression Anxiety Stress Scales (DASS-21), Kessler Psychological Distress Scale (K10)	Australia	I	Depression	Australia, USA, UK, Canada, Norway, Germany	Mihalopoulos, 2014 [64]
AQoL-8D	Diabetes-39	Australia	I	Diabetes	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [65]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
AQoL-8D	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	Australia	I	Gastric cancer	Greece	Kontodimopoulos, 2009 [73]
AQoL-8D	Fibromyalgia Impact Questionnaire (FIQR)	Australia	I	Fibromyalgia	Spain	Collado-Mateo, 2017 [67]
AQoL-8D	Incontinence Quality of Life (I-QOL)	Australia	I	Overactive bladder	Australia, Canada, France, Germany, Italy, Spain, UK, USA	Chen, 2014 [74]
AQoL-8D	MacNew Heart Disease Quality of Life Questionnaire	Australia	I	Heart disease	Australia, USA, UK, Canada, Norway, Germany	Chen, 2014 [68]
AQoL-8D	Sydney Asthma Quality of Life Questionnaire (AQLQ-S)	Australia	I	Asthma	multi-country	Kaambwa, 2016 [69]
CHU-9D	KIDSCREEN-10 index	UK	I	Adolescents (11-17yrs)	Australia	Chen, 2014 [75]
CHU-9D	Paediatric Quality of Life Inventory (PedsQL)	UK	I	Corticosteroid-sensitive nephrotic syndrome patients (2-18yrs)	UK	Lambe, 2018 [76]
CHU-9D	Strengths and Difficulties Questionnaires (SDQ) - caregiver version	Australian	I	Children receiving mental health care (5-17yrs) (parent or relative assessment)	Australia	Furber, 2014 [77]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
CHU-9D	Weight-Specific Adolescent Instrument for Economic Evaluation (WAIIE)	UK	I,D	Adolescents (11-18yrs)	UK	Robinson, 2018 [78]
EQ-5D-3L	Achilles Tendon Rupture Score (ATRS)	UK	I	Achilles tendon rupture	Sweden	Hua, 2018 [79]
EQ-5D-3L	Acromegaly Quality of Life Questionnaire (ACROQOL)	UK	I,D	Acromegaly patients	Netherlands, Spain and UK	Badia, 2018 [80]
EQ-5D-3L	American Shoulder and Elbow Surgeons (ASES) score and the Constant score	USA	I	Shoulder diagnoses (various)	USA	Bafus, 2012 [81]
EQ-5D-3L	Ankylosing spondylitis disease activity score with C reactive protein (ASDAS-CRP), Bath ankylosing spondylitis functional index (BASFI)	UK	I	Ankylosing spondylitis	Czech republic	Mlcoch, 2016 [82]
EQ-5D-3L	Barthel Index	UK	I,D	Intermediate care patients	UK	Kaabmwa, 2011 [83]
EQ-5D-3L	Bath Ankylosing Spondylitis Disease Activity Index( BASDAI), Bath Ankylosing Spondylitis Functional Index (BASAF)	UK	I,D	Ankylosing spondylitis	Wales	Wailoo, 2015 [84]
EQ-5D-3L	Beck depression inventory (BDI)	UK	I	Depression	Germany	Grochtdreis, 2016 [85]
EQ-5D-3L	Catquest	UK	I	Cataract	Iran	Yousefi, 2016 [86]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Clinical chronic obstructive pulmonary disease questionnaire (CCQ)	Dutch, UK, USA	I	Chronic Obstructive Pulmonary Disease (COPD)	Netherlands	Boland, 2015 [87]
EQ-5D-3L	COPD assessment test (CAT)	UK	I, D	Chronic Obstructive Pulmonary Disease (COPD)	Multi-country	Hoyle, 2016 [88]
EQ-5D-3L	CushingQOL	UK	I	Cushing's syndrome	Europe	Badia, 2013 [89]
EQ-5D-3L	Cystic Fibrosis Questionnaire (CFQ-R)	UK	I	Cystic Fibrosis	UK	Acaster, 2015 [90]
EQ-5D-3L	Daily Symptom Score (DSS), Daily Medication Score (DMS)	UK	I	Seasonal allergic rhinoconjunctivitis	Austria, Denmark, Germany, Italy, The Netherlands, Spain, Sweden, UK	Poole, 2014 [91]
EQ-5D-3L	Dermatology Life Quality Index (DLQI)	UK	D	Skin diseases	Multi-country Europe (n=13)	Ali, 2017 [92]
EQ-5D-3L	Dermatology life quality index (DLQI)	German	I	Psoriasis	Germany	Blome, 2013 [93]
EQ-5D-3L	Dermatology Life Quality Index (DLQI)	UK	I,D	Psoriasis	UK and Eire	Davison, 2018 [94]
EQ-5D-3L	Dermatology Life Quality Index (DLQI)	UK	I	Psoriasis	Hungary	Heredi, 2014 [95]
EQ-5D-3L	Dermatology Life Quality Index (DLQI)	UK	I	Psoriasis	Sweden	Norlin, 2012 [96]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Disease Activity Index for PsA (DAPsA), clinical DAPsA, Health Assessment Questionnaire disability index (HAQ)	UK	I	Psoriatic arthritis	Czech Republic	MIcoch, 2018 [97]
EQ-5D-3L	EQ-5D-5L	Multi-country (n=10)	I,D	Mixed patient group	Denmark, England, The Netherlands, Italy, Poland, Scotland	Van Hout, 2012 [40]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I	Breast cancer	Belgium, France, the Netherlands, Switzerland, and the UK	Crott, 2010 [98]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	USA	I	Non-small cell lung cancer	Canada	Jang, 2010 [99]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I	Non-small cell lung cancer	UK	Khan, 2014 [100]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30) / Myeloma-specific module QLQ-MY20	UK	I	Multiple Myeloma	UK, New Zealand, South Africa	Kharroubi, 2015 [101]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30) / Myeloma-specific module QLQ-MY20	UK	I	Myeloma patients	UK, New Zealand, South Africa	Kharroubi, 2018 [102]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)/ EORTC QLQ-BR23	Korean	I	Various cancers	Korea	Kim, 2011 [103]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	Korean	I	Breast cancer	Korea	Kim, 2012 [104]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I	Gastric cancer	Greece	Kontodimopoulos, 2009 [73]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I	Colorectal cancer	Australia, New Zealand, Europe, Israel and USA	Marriott, 2016 [105]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I,D	Oesophageal cancer	UK	McKenzie, 2009 [106]
EQ-5D-3L	European Organization for Research and Treatment of Cancer	UK	I	Multiple myeloma	UK, Germany	Proskorovsky, 2014 [107]



Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
	Quality of Life Questionnaire (EORTC QLQ C30) / Myeloma-specific module EORTC QLQ-MY20					
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30) / Health Assessment Questionnaire (HAQ)	Dutch and UK	I	Multiple myeloma, Non-Hodgkin's lymphoma, Rheumatoid arthritis	Netherlands	Versteegh, 2010 [108]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)/ Health Assessment Questionnaire (HAQ)/ MSIS-29 (Multiple sclerosis impact scale)	Dutch and UK	I	Multiple myeloma, Non-Hodgkin's lymphoma, Rheumatoid arthritis, Multiple sclerosis	Netherlands	Versteegh, 2011 [109]
EQ-5D-3L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I,D	Cancer	Australia	Woodcock, 2018 [110]
EQ-5D-3L	European union foundation of osteoporosis quality-of-life assessment (Qual EFO), Osteoporosis assessment questionnaire (OPAQ), Nottingham health profile (NHP)	NR	I	Osteoporosis	Australia, Canada, New Zealand, USA, Belgium, UK, Netherlands, Sweden	Burge, 2013 [111]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Extended 36 item version of the inflammatory bowel disease questionnaire (IBDQ-36)	Spanish	I	Ulcerative colitis or Crohn's disease	Spain	Huaman, 2010 [112]
EQ-5D-3L	Fibromyalgia Impact Questionnaire (FIQR)	Spain	I	Fibromyalgia	Spain	Collado-Mateo, 2017 [67]
EQ-5D-3L	Functional assessment of cancer therapy - breast (FACT-B)	Japanese	I	Breast cancer	Singapore	Cheung, 2014 [113]
EQ-5D-3L	Functional assessment of cancer therapy - general (FACT-G)	Japanese	I	Cancer outpatients	Singapore	Cheung, 2009 [114]
EQ-5D-3L	Functional assessment of cancer therapy - general (FACT-G)	USA	I	Breast cancer, colorectal cancer, lung cancer	Canada	Teckle, 2013 [115]
EQ-5D-3L	Functional assessment of cancer therapy - general (FACT-G), EORTC QLQ-C30	UK	I,D	Various cancers	USA and Canada	Young, 2015 [116]
EQ-5D-3L	Functional assessment of cancer therapy - melanoma (FACT-M), FACT-G (general)	USA	I	Melanoma	USA	Askew, 2011 [117]
EQ-5D-3L	Functional assessment of cancer therapy - prostate (FACT-P)	UK	I	Prostate cancer (mCRPC)	Belgium, France, Germany, Sweden, the Netherlands and the UK	Diels, 2014 [118]
EQ-5D-3L	Functional assessment of cancer therapy - prostate (FACT-P)	UK	I	Prostate cancer (mCRPC)	France, Germany, Italy, Spain, UK	Skaltsa, 2014 [119]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Functional assessment of cancer therapy - prostate (FACT-P), EORTC QLQ-C30	UK	I	Prostate cancer	North America, Europe, Australia	Wu, 2007 [120]
EQ-5D-3L	Gastrointestinal Short Form Questionnaire (GSF-Q)	UK	I	Gastroesophageal reflux disease	Spain	Monroy, 2018 [121]
EQ-5D-3L	General Health question (excellent to poor)	UK	I,D	Various health conditions	England	Ara, 2014 [122]
EQ-5D-3L	General Health Questionnaire (GHQ-12)	UK and Swedish	I	General population	Sweden	Lindkvist, 2016 [123]
EQ-5D-3L	General Health Questionnaire (GHQ-12)	Spanish	I	General population	Canary Islands (Spain)	Serrano, 2009 [124]
EQ-5D-3L	Glasgow Outcome Scale	UK	I	Traumatic injuries	Australia	Ward, 2017 [125]
EQ-5D-3L	Headache Impact Test 6 (HIT-6) and Migraine-specific Quality of Life Questionnaire (MSQ)	UK, USA	I	Migraine	USA, Australia, Canada, Germany, United Kingdom, France, Spain, Italy, Taiwan	Gillard, 2012 [126]
EQ-5D-3L	Health Assessment Questionnaire (HAQ)	UK	I	Rheumatoid arthritis	UK and Canada	Bansback, 2007 [127]
EQ-5D-3L	Health assessment questionnaire (HAQ)	UK	I	Rheumatoid arthritis	UK	Hernandez Alava, 2012 [128]
EQ-5D-3L	Health assessment questionnaire (HAQ)	UK, USA	I	Rheumatoid arthritis	USA	Wolfe, 2010 [129]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Health Assessment Questionnaire (HAQ) and disease activity score (DAS28)	Dutch	I	Rheumatoid arthritis	The Netherlands	Nair, 2015 [130]
EQ-5D-3L	Health assessment questionnaire (HAQ) and VAS Pain	UK	I,D	Rheumatoid arthritis	USA	Hernandez Alava, 2013 [131]
EQ-5D-3L	Health assessment questionnaire (HAQ), Disease activity score (DAS28)	UK	I	Rheumatoid arthritis, psoriatic arthritis	Ireland	Adams, 2010 [132]
EQ-5D-3L	Health Assessment Questionnaire Disability Index (HAQ-DI)	Spain	I	Rheumatoid arthritis	Spain	Carreno, 2011 [133]
EQ-5D-3L	Health Assessment Questionnaire Disability Index (HAQ-DI), pain Visual Analog Scale (VAS), and Disease Activity Score in, 28 joints (DAS28)	Korean	I	Rheumatoid arthritis	Korea	Kim, 2016 [134]
EQ-5D-3L	Healthy days	USA	I	General population (aged 35 to 89)	USA	Jia, 2011 [135]
EQ-5D-3L	Hospital anxiety and depression scale (HADS), Patient Health Questionnaire (PHQ-9), Generalised anxiety disorder assessment (GAD-7), Clinical outcomes in routine evaluation - outcome measurement (CORE-OM), General health questionnaire (GHQ-12)	UK	I,D	Various mental health conditions	UK	Brazier, 2014 [35]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Incontinence Quality of Life Questionnaire (I-QOL)	UK, USA	I	Overactive bladder disease	France, Germany, Spain, UK	Kay, 2013 [136]
EQ-5D-3L	Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Disease Activity Index (CDAI)	UK	I	Crohn's disease	Multinational	Buxton, 2007 [137]
EQ-5D-3L	Insomnia Severity Index (ISI)	USA	I	Sleep problems	USA	Gu, 2011 [138]
EQ-5D-3L	Macular degeneration Quality of Life instrument (MacDQoL)	UK	I	Age-related macular degeneration	UK	Dixon, 2016 [139]
EQ-5D-3L	MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT)	USA	I	Brain tumour patients (malignant glioma)	USA	Vera, 2018 [140]
EQ-5D-3L	Medical Outcomes Study HIV (MOS-HIV)	USA	I	HIV (human immunodeficiency virus)	USA	Huang, 2007 [141]
EQ-5D-3L	Medical Outcomes Study HIV (MOS-HIV)	Canada, USA	I	HIV (human immunodeficiency virus)	UK, Canada and USA	Joyce, 2017 [142]
EQ-5D-3L	Modified Rankin Scale (mRS)	Multi-country weights (n=13)	I	Stroke	Multi-country (n=13)	Ali, 2016 [143]
EQ-5D-3L	Modified Rankin Scale (mRS)	UK	I,D	Stroke and transient ischaemic attack (TIA)	UK	Rivero-Arias, 2009 [144]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Modified Rankin Score (mRS) + Barthel Index + Short Zung Depression Scale	UK	I,D	Stroke	Multi-country (n=16)	Whynes, 2012 [145]
EQ-5D-3L	Modified Health Assessment Questionnaire (MHAQ)	UK	I	Rheumatoid arthritis	Greece	Kontodimopoulo, 2012 [146]
EQ-5D-3L	Moorehead-Ardelt II questionnaire (MA-II)	European	I	Morbid obesity	Germany, Czechoslovakia, Italy, Spain	Sauerland, 2009 [147]
EQ-5D-3L	Multiple Sclerosis Impact Scale (MSIS-29)	UK	I	Multiples sclerosis	UK	Hawton, 2012 [148]
EQ-5D-3L	Multiple Sclerosis Walking Scale (MSWS-12)	UK	I	Multiples sclerosis	UK	Hawton, 2011 [149]
EQ-5D-3L	Multiple Sclerosis Walking Scale (MSWS-12)	USA	I	Multiple sclerosis	North America (USA & Canada)	Sidovar, 2013 [150]
EQ-5D-3L	National eye institute visual functioning questionnaire (NEI VFQ-25)	UK	I	Diabetic macular edema	Multi-country (n=13)	Kay, 2014 [151]
EQ-5D-3L	National Eye Institute Vision Function Questionnaire (NEI VFQ, 25)	UK	I	Glaucoma	UK	Browne, 2012 [152]
EQ-5D-3L	National Eye Institute Vision Function Questionnaire (NEI VFQ, 25)	UK	I	Age-related macular degeneration	Australia, Netherlands, UK and USA	Payakachat, 2009 [153]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Neck disability index (NDI) and neck pain score, and arm pain score	USA	I	Degenerative cervical spine disorders	USA	Carreon, 2014 [154]
EQ-5D-3L	Nottingham Health Profile (NHP)	UK	I	Diabetes	Hungary	Voko, 2014 [155]
EQ-5D-3L	Osteoporosis Assessment Questionnaire	USA	I	Osteoporosis-related fracture	USA	McDonough, 2011 [156]
EQ-5D-3L	Overactive Bladder Questionnaire 5-dimensional health classification system (OAB-5D)	Spanish	I	Overactive bladder	Spain	Ruiz, 2016 [157]
EQ-5D-3L	Oxford Hip Score	UK	I	Hip replacement	UK	Hernandez Alava, 2015 [158]
EQ-5D-3L	Oxford Hip Score	UK	I	Hip replacement	UK	Oppe, 2011 [159]
EQ-5D-3L	Oxford Hip Score	UK	I,D	Hip replacement	UK	Pinedo-Villanueva, 2012 [160]
EQ-5D-3L	Oxford Knee Score	UK	I, D	Knee replacement	UK	Dakin, 2013 [161]
EQ-5D-3L	painDETECT	USA	I,D	Neuropathic pain	USA	Cappelleri, 2016 [162]
EQ-5D-3L	Palliative care Outcome Scale	UK	I, D	Cancer, Parkinson's, breathlessness in advanced disease	UK	Dzingina, 2017 [163]
EQ-5D-3L	Parkinson's Disease Questionnaire (PDQ-39)	UK	I,D	Parkinson's disease	Spain	Borchani, 2012 [164]
EQ-5D-3L	Parkinson's Disease Questionnaire (PDQ-39)	UK	I,D	Parkinson's disease	UK	Kent, 2015 [165]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Parkinson's Disease Questionnaire (PDQ-39)	UK	I,D	Parkinson's disease	Australia	Young, 2012 [166]
EQ-5D-3L	Parkinson's disease Questionnaire (PDQ-8)	Japanese	I	Parkinson's disease	Singapore	Cheung, 2008 [167]
EQ-5D-3L	Patient Assessment of Constipation Quality of Life (PAC-QOL)	UK	I	Constipation	USA and EU	Hatswell, 2016 [168]
EQ-5D-3L	Patient-Reported Outcomes Measurement Information System (PROMIS)	USA	I	General population	USA	Hartman, 2018 [169]
EQ-5D-3L	Patient-Reported Outcomes Measurement Information System (PROMIS)	USA	I	Various conditions	USA	Revicki, 2009 [170]
EQ-5D-3L	Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health	USA	I	General population	USA	Thompson, 2017 [171]
EQ-5D-3L	Pruritus-VAS	Korean	I	General population	South Korea	Park, 2017 [172]
EQ-5D-3L	Psoriasis Area and Severity Index (PASI)	UK and Swedish	I	Psoriasis	Sweden	Geale, 2017 [173]
EQ-5D-3L	QoL Assessment of Growth Hormone Deficiency in Adults questionnaire (QoLAGHDA)	European	I	General population	Sweden	Koltowska-Haggstrom, 2007 [174]
EQ-5D-3L	Roland Morris Questionnaire	UK	I,D	Lower back pain	UK	Khan, 2014 [175]



Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Roland-Morris Disability Questionnaire Pain numerical ratings scale	USA	I	Back pain (age 65 or older)	USA	Rundell, 2014 [176]
EQ-5D-3L	Scoliosis Research Society, 22-item (SRS-22r)	Chinese	I	Scoliosis	China	Wong, 2017 [177]
EQ-5D-3L	Seattle Angina Questionnaire (SAQ)	UK	I	Heart disease	UK	Goldsmith, 2010 [178]
EQ-5D-3L	Seattle Angina Questionnaire (SAQ)	USA	I	Heart disease	Canada	Wijeyesundera, 2010 [179]
EQ-5D-3L	SF-12	USA	I, D	General population	USA	Chuang, 2009 [180]
EQ-5D-3L	SF-12	USA	I	General population	USA	Coca Perrailon, 2015 [181]
EQ-5D-3L	SF-12	USA and UK	D	General population	USA and UK	Conigliani, 2014 [182]
EQ-5D-3L	SF-12	UK	I,D	General population	USA	Le, 2011 [183]
EQ-5D-3L	SF-12	USA	I,D	General population	USA	Le, 2013 [184]
EQ-5D-3L	SF-36	UK	I	Various health conditions	NR	Ara, 2008 [185]
EQ-5D-3L	SF-36	Korean	I,D	General population, Diabetes, Stroke	Korea	Kim, 2014 [186]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	SF-36	UK	I	Various health conditions	UK	Rowen, 2009 [187]
EQ-5D-3L	SF-36 & pain VAS	UK	I	Rotator cuff disease	UK	Neilson, 2013 [188]
EQ-5D-3L	Sino-Nasal Outcome Test (SNOT-22)	Canadian	I	Rhinosinusitis	Canada	Crump, 2017 [189]
EQ-5D-3L	St Georges Respiratory Questionnaire (SGRQ)	UK	I	Patients with moderate, severe or very severe COPD	Multicentre trial data from 41 non-USA countries	Starkie, 2011 [190]
EQ-5D-3L	The Quality of Life-Assessment for Growth Hormone Deficiency in Adults (QoL-AGHDA)	Dutch	I	General Population	Belgium and the Netherlands	Busschback, 2010 [191]
EQ-5D-3L	Ulcerative Colitis Disease Activity Scale (UCDAI)	NR (refer to appropriate tariff)	D	Ulcerative colitis	France, UK, Spain, Germany, the Netherlands, and Sweden	Poole, 2010 [192]
EQ-5D-3L	Unified Parkinson's Disease Rating Scale (UPDRS) (clinical measure) and Parkinson's Disease Questionnaire (PDQ-8)	German, European (EQ-VAS)	I	Parkinson's disease	Germany	Dams, 2013 [193]
EQ-5D-3L	University of Washington Quality of Life Questionnaire (UW-QOL)	not stated	I	Head and neck cancer	Canada	Chan, 2013 [194]
EQ-5D-3L	Western & Ontario McMasters Universities Osteoarthritis Index (WOMAC)	UK	I	Knee pain	UK	Barton, 2008 [195]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-3L	Western & Ontario McMaster Universities Osteoarthritis Index (WOMAC)	UK	I	Knee or hip osteoarthritis	Spain	Wailoo, 2014 [196]
EQ-5D-3L	Western & Ontario McMaster Universities Osteoarthritis Index (WOMAC)	Japanese	I	Knee osteoarthritis	Singapore	Xie, 2010 [197]
EQ-5D-3L (mapped from SF-36)	Patient Assessment of Constipation – Quality of Life (PAC-QOL), Patient Assessment of Constipation (measuring symptoms) (PAC-SYM)	UK	I	Constipation	Unknown	Parker, 2011 [198]
EQ-5D-5L	15D, AQoL-8D, HUI3, QWB, SF-6D	UK	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [62]
EQ-5D-5L	15D, AQoL-8D, HUI3, QWB, SF-6D	UK	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Richardson, 2014 [63]
EQ-5D-5L	Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), Neuropathic pain Scale, MND Hospital and Anxiety Depression Scale	England	I,D	Motor Neurone Disease	UK	Moore, 2018 [199]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-5L	Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM), Leeds Dependence Questionnaire (LDQ), and the Treatment Outcomes Profile (TOP)	England	I	Substance abuse (heroin)	England	Peak, 2018 [200]
EQ-5D-5L	Depression Anxiety Stress Scales (DASS21) and the Kessler Psychological Distress Scale (K-10)	Multi-country (n=8)	I	Depression	Australia, Canada, Germany, Norway, UK and the USA	Gamst-Klaussen, 2018 [201]
EQ-5D-5L	Depression Anxiety Stress Scales (DASS-21), Kessler Psychological Distress Scale (K10)	UK	I	Depression	Australia, USA, UK, Canada, Norway, Germany	Mihalopoulos, 2014 [64]
EQ-5D-5L	Diabetes-39	UK	I	Diabetes	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [65]
EQ-5D-5L	Diabetes-39 (D-39)	Multi-country (n=8)	I	Diabetes	Australia, Canada, Germany, Norway, UK and USA	Lamu, 2018 [202]
EQ-5D-5L	EQ-5D-3L	UK and England	D	Rheumatoid Arthritis	UK	Hernandez-Alava, 2017 [203]
EQ-5D-5L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	England	I	Cancer	Iran	Ameri, 2018 [204]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-5L	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	England	I,D	Cancer	Australia, Canada, Germany, Norway, UK and the USA	Lamu, 2018 [205]
EQ-5D-5L	Functional Assessment of Cancer Therapy—Breast (FACT-B)	Japan	I	Breast cancer	Singapore	Lee, 2018 [206]
EQ-5D-5L	Health Assessment Questionnaire Disability Index (HAQ-DI), HAQ Pain VAS	China	I,D	Rheumatoid arthritis	China	Patton, 2018 [207]
EQ-5D-5L	MacNew Heart Disease Quality of Life Questionnaire	UK	I	Heart disease	Australia, USA, UK, Canada, Norway, Germany	Chen, 2014 [68]
EQ-5D-5L	Menopause-Specific Quality of Life (MENQOL)	USA (crosswalk)	I	Postmenopausal women	USA	Coon, 2018 [208]
EQ-5D-5L	Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief)	England	I,D	General population (aged over 65rs)	Australia	Kaambwa, 2017 [209]
EQ-5D-5L	Positive and Negative Syndrome Scale (PANSS)	UK	I	Schizophrenia spectrum disorder	Singapore	Abdin 2018 [210]
EQ-5D-5L	Quality of Life in Epilepsy Inventory (QOLIE-31)	UK and Dutch	I	Epilepsy	UK and Netherlands	Wijnen, 2017 [211]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
EQ-5D-5L	Sydney Asthma Quality of Life Questionnaire (AQLQ-S)	England	I	Asthma	Australia, Canada, Germany, Norway, UK and the USA	Gray, 2018 [212]
EQ-5D-5L	Sydney Asthma Quality of Life Questionnaire (AQLQ-S)	UK	I	Asthma	Australia, Canada, Germany, Norway, UK and the USA	Kaambwa, 2016 [69]
EQ-5D-5L	Women's Health Questionnaire (WHQ-23)	UK	I,D	Women (18-45yrs)	Australia	Kaambwa, 2018 [213]
EQ-5D-5L	World Health Organization Quality of Life Questionnaire (WHOQOL-BREF)	Japan	I	General population and 2 outpatient clinics in acute care hospitals	Singapore	Wee, 2018 [214]
EQ-5D-Y	Pediatric Quality of Life Inventory (PedsQL™) General Core Scales (GCS)	UK	I,D	Children (11-15yrs)	England	Khan, 2014 [215]
HUI2	European union foundation of osteoporosis quality-of-life assessment (Qual EFFO), Osteoporosis Assessment Questionnaire (OPAQ), Nottingham Health Profile (NHP)	Canada	I	Osteoporosis	Australia, Canada, New Zealand, USA, Belgium, UK, Netherlands, Sweden	Burge, 2013 [111]
HUI2, HUI3	Otitis media questionnaire (OM8-30)	Canada	I	Bilateral otitis media with effusion (4-11 yrs.)	UK	Dakin, 2010 [216]
HUI3	15D, AQoL-8D, EQ-5D-5L, QWB, SF-6D	Canada	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [62]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
HUI3	15D, AQoL-8D, EQ-5D-5L, QWB, SF-6D	Canada	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Richardson, 2014 [63]
HUI3	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory	Canada	I, D	Dementia (caregiver assessment)	Singapore	Cheung, 2018 [217]
HUI3	Child Behavior Checklist, Vineland II Adaptive Behavior Scales, and the Pediatric Quality of Life Inventory (PedsQL™) 4.0	Canada	I	Children (4-17yrs) with Autistic Spectrum Disorder	USA	Payakachat, 2014 [218]
HUI3	Depression Anxiety Stress Scales (DASS-21), Kessler Psychological Distress Scale (K10)	Canada	I	Depression	Australia, USA, UK, Canada, Norway, Germany	Mihalopoulos, 2014 [64]
HUI3	Diabetes-39	Canada	I	Diabetes	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [65]
HUI3	Health Assessment Questionnaire Disability Index (HAQ-DI)	Spain	I	Rheumatoid arthritis	Spain	Carreno, 2011 [133]
HUI3	MacNew Heart Disease Quality of Life Questionnaire	Canada	I	Heart disease	Australia, USA, UK, Canada, Norway, Germany	Chen, 2014 [68]
HUI3	Medical Outcomes Study HIV (MOS-HIV)	Canada	I	HIV (human immunodeficiency virus)	UK, Canada and USA	Joyce, 2017 [142]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
HUI3	Patient reported outcomes measure information system (PROMIS)	Canada	I	General population	USA	Hays, 2016 [219]
HUI3	Sydney Asthma Quality of Life Questionnaire (AQLQ-S)	Canada	I	Asthma	Australia, USA, UK, Canada, Norway, Germany	Gray, 2018 [212]
QWB-SA	15D, AQoL-8D, EQ-5D-5L, HUI3, SF-6D	USA	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [62]
QWB-SA	15D, AQoL-8D, EQ-5D-5L, HUI3, SF-6D	USA	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Richardson, 2014 [63]
QWB-SA	Diabetes-39	USA	I	Diabetes	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [65]
QWB-SA	MacNew Heart Disease Quality of Life Questionnaire	USA	I	Heart disease	Australia, USA, UK, Canada, Norway, Germany	Chen, 2014 [68]
SF-6D (SF-12)	Fibromyalgia Impact Questionnaire (FIQR)	UK	I	Fibromyalgia	Spain	Collado-Mateo, 2017 [67]
SF-6D (SF-12)	Functional Assessment of Cancer Therapy-Colorectal (FACT-C) [Chinese]	Hong Kong	I	Colorectal polyp or cancer	Hong Kong	Yang et al, 2014 [220]



Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
SF-6D (SF-36)	15D, AQoL-8D, EQ-5D-5L, HUI3, QWB	UK	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [62]
SF-6D (SF-36)	15D, AQoL-8D, EQ-5D-5L, HUI3, QWB	UK	I	Multi-instrument Comparison (MIC) dataset <sup>ϕ</sup>	Australia, USA, UK, Canada, Norway, Germany	Richardson, 2014 [63]
SF-6D (SF-36)	Cambridge Otology Quality of Life instrument (COQOL)	UK	I	Otology clinic patients	UK	Frew, 2015 [221]
SF-6D (SF-36)	Cervical Spine Outcomes Questionnaire (CSOQ)	UK	I	Cervical spine patients	USA	Skolasky , 2011 [222]
SF-6D (SF-36)	Change in Incontinence Quality of Life Instrument (I-QoL) and urinary incontinence episodes	UK	I	Urinary Incontinence	Belgium, France and Switzerland	Hollingworth, 2010 [223]
SF-6D (SF-36)	Chronic liver disease questionnaire (CLDQ)	UK	I	Primary sclerosing cholangitis (PSC)	Sweden and England	Kalaitzakis, 2015 [224]
SF-6D (SF-36)	Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV)	UK	I	Hepatitis C	North America, Europe, Australia, New Zealand	Stepanova, 2018 [225]
SF-6D (SF-36)	CushingQoL	UK	I	Cushing's Syndrome	Spain, France, Germany, the Netherlands, and Italy	Roset, 2013 [226]
SF-6D (SF-36)	Depression Anxiety Stress Scales (DASS-21), Kessler Psychological Distress Scale (K10)	UK	I	Depression	Australia, USA, UK, Canada, Norway, Germany	Mihalopoulos, 2014 [64]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
SF-6D (SF-36)	Diabetes-39	UK	I	Diabetes	Australia, USA, UK, Canada, Norway, Germany	Chen, 2015 [65]
SF-6D (SF-36)	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I	Cancer	Iran	Ameri, 2018 [204]
SF-6D (SF-36)	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I	Gastric cancer	Greece	Kontodimopoulos, 2009 [73]
SF-6D (SF-36)	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30)	UK	I, D	Cancer	Australia, Canada, Germany, Norway, UK and the USA	Lamu, 2018 [205]
SF-6D (SF-36)	European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ C30 and QLQ-CR29) [Chinese]	Hong Kong	I	Colorectal cancer	Hong Kong	Wong et al, 2013 [227]
SF-6D (SF-36)	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	UK	I	Various cancers	Greece	Kontodimopoulos, 2014 [228]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
SF-6D (SF-36)	Functional Assessment of Cancer Therapy-General (FACT-G)	UK	I	Breast cancer, colorectal cancer, lung cancer	Canada	Teckle, 2013 [115]
SF-6D (SF-36)	Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) [Chinese]	Hong Kong	I	Colorectal polyp or cancer	Hong Kong	Wong et al, 2012 [229]
SF-6D (SF-36)	Gastrointestinal Quality of Life Index (GIQLI)	UK	I	Laparoscopic cholecystectomy patients	Canada	Lee, 2013 [230]
SF-6D (SF-36)	Gastrointestinal Short Form Questionnaire (GSF-Q)	UK	I	Gastroesophageal reflux disease	Spain	Monroy, 2018 [121]
SF-6D (SF-36)	Health assessment questionnaire (HAQ)	UK	I	Rheumatoid arthritis	UK and Canada	Bansback, 2007 [127]
SF-6D (SF-36)	Health assessment questionnaire (HAQ)	UK	I	Rheumatoid arthritis	USA	Wolfe, 2010 [129]
SF-6D (SF-36)	Health assessment questionnaire (HAQ) , Disease Activity score (DAS28)	UK	I	Rheumatoid arthritis, psoriatic arthritis	Ireland	Adams, 2010 [132]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
SF-6D (SF-36)	Hospital anxiety and depression scale (HADS), Patient Health Questionnaire (PHQ-9), Generalised anxiety disorder assessment (GAD-7), Clinical outcomes in routine evaluation - outcome measurement (CORE-OM), General health questionnaire (GHQ-12)	UK	I,D	Various mental health conditions	UK	Brazier, 2014 [35]
SF-6D (SF-36)	Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Disease Activity Index (CDAI)	UK	I	Crohn's disease	Multinational	Buxton, 2007 [137]
SF-6D (SF-36)	LupusQoL	UK	I	Systemic lupus erythematosus (SLE)	UK	Meacock, 2014 [231]
SF-6D (SF-36)	MacNew (Heart Disease Quality of Life Questionnaire)	UK	I	Heart disease	Australia, USA, UK, Canada, Norway, Germany	Chen, 2014 [68]
SF-6D (SF-36)	Medical Outcomes Study (MOS) Sleep Scale	UK	I	Various health conditions	USA	Yang, 2007 [232]
SF-6D (SF-36)	Moorehead-Ardelt II questionnaire (MA-II)	UK	I	Morbid obesity	Germany, Czechoslovakia, Italy, Spain	Sauerland, 2009 [146, 147]
SF-6D (SF-36)	Multiple Sclerosis Impact Scale (MSIS-29)	UK	I	Multiples sclerosis	UK	Hawton, 2012 [148]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
SF-6D (SF-36)	National eye institute visual functioning questionnaire (NEI VFQ-25)	UK	I	Glaucoma	UK	Browne, 2012 [152]
SF-6D (SF-36)	Neck Disability Index (NDI)	UK	I	Cervical disc disease	USA	Richardson, 2012 [233]
SF-6D (SF-36)	Neck Disability Index (NDI)	UK	I	Neck pain	China	Zheng et al, 2016 [234]
SF-6D (SF-36)	Neck Disability Index (NDI), Neck pain scores, arm pain scores	UK	I	Degenerative disorders	Not stated	Carreon, 2011 [235]
SF-6D (SF-36)	Osteoporosis Assessment Questionnaire	UK	I	Osteoporosis-related fracture	USA	McDonough, 2011 [156]
SF-6D (SF-36)	Oswestry Disability Index (ODI), Back Pain Numeric Rating Scale (BPNRS), Leg Pain Numeric Rating Scale (LPNRS)	UK	I	Degenerative disorders	Not stated	Carreon, 2009 [236]
SF-6D (SF-36)	Patient Assessment of Constipation – Quality of Life (PAC-QOL), Patient Assessment of Constipation (measuring symptoms) (PAC-SYM)	UK	I	Constipation	Not stated	Parker, 2011 [198]
SF-6D (SF-36)	Positive and Negative Syndrome Scale (PANSS)	UK	I	Schizophrenia spectrum disorder	Singapore	Abdin, 2018 [210]
SF-6D (SF-36)	Roland Morris Questionnaire	UK	I,D	Lower back pain	UK	Khan, 2014 [175]
SF-6D (SF-36)	SF-12 vs 1	UK	I	General population	USA	Hanmer, 2009 [237]

Target measure	Start measure	HSUV country weights	Mapped to HSUV index (I) or dimension (D)	Population	Country	Author, Year
SF-6D (SF-36)	SF-8	UK	I	General population	Singapore	Wang et al, 2012 [238]
SF-6D (SF-36)	Sydney Asthma Quality of Life Questionnaire (AQLQ-S)	UK	I	Asthma	Multi-country	Kaambwa, 2016 [69]
SF-6D (SF-36)	Veterans Rand Health Survey (VR-12)	UK	I	Various conditions	USA	Selim, 2011 [239]
SF-6D (SF-36)	Women's Health Questionnaire (WHQ-23)	UK	I,D	Women (18-45yrs)	Australia	Kaambwa, 2018 [213]

Notes: Φ Multi Instrument Comparison (MIC) dataset: Healthy people plus patients for 7 disease areas: arthritis, asthma, cancer, depression, diabetes, hearing loss, heart disease

Highlighted rows indicate mapping functions reported in papers that estimate mapping functions to more than one preference-based measure.

HSUV- Health state utility values; I – Index; D – Dimension

15D – 15 Dimensions; AQoL-4/8D – Assessment of Quality of Life 4 or 8 Dimensions; CHU-9D – Child Health Utility – 9 Dimensions; EQ-5D-3L – EQ-5D three level version; EQ-5D-5L – EQ-5D five level version; EQ-5D-Y – EQ-5D youth version; HUI2/3 – Health Utilities Index 2 or 3; QWB – Quality of Wellbeing Scale; SF-6D – Short Form – 6 Dimensions; SF-12 – Short Form 12 ; SF-36 – Short Form 36; UK – United Kingdom; USA – United States of America